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During the early 1950s, American researchers enrolled over 55,000 healthy children in a 
medical experiment to assess whether the blood fraction, gamma globulin (GG), could be used as a 
means to prevent paralytic polio.1-6 Since a large double-blind placebo controlled study had never 
been attempted on an open population before, publicity became an inextricable part of the design.7 
Although marketing the experiment was successful and clinic attendance surpassed researchers’ 
expectations, the enthusiasm of parents and health professionals led to unforeseen consequences. 
Researchers struggled to maintain control of the experiment and subsequently suppressed the 
extent of the problems and did not acknowledge the implications for medical science. The successes 
and setbacks of this study later influenced the Salk vaccine trials in 1954, while also raising important 
questions about the conduct of one of the first “gold standard” clinical trials. 
Before a safe and effective polio vaccine was licensed in April 1955, Americans faced the 
constant threat of polio outbreaks. Caused by an oral-fecal virus, a polio infection could lead to 
paralysis of the limbs and respiratory muscles, or in extreme cases, death. Although anyone could 
contract the disease, children seemed the most susceptible, inspiring the term “infantile paralysis.”8-
9 Desperate for a means to prevent polio disability, the National Foundation for Infantile Paralysis 
(now known as the March of Dimes) backed University of Pittsburgh researcher Dr. William McD. 
Hammon to undertake a controlled study with GG. The blood fraction, rich in antibodies, was 
already used for the prevention of measles and hepatitis and was therefore considered safe. 
Hammon hoped that by randomly injecting 4 cc to 11 cc of either placebo solution or GG into the 
gluteus maximus of children and comparing the two groups, the value of the blood fraction for polio 
could be established. 
Hammon and Foundation officials believed that a publicity program was necessary to 
encourage parents to volunteer their healthy children. The Foundation drew on its vast marketing 
expertise and connections to develop a sophisticated campaign for Hammon’s experiment.  Unlike 
the annual March of Dimes polio fundraising drive, which benefited from weeks of advance publicity, 
promoting the GG trial would be limited to days, since it was difficult to predict an epidemic and 
once identified, the epidemic would not last long. Moreover, parents would need to be educated to 
appreciate the value of controlled trial methodology in which only half of the cohort would receive 
the potentially protective substance. Hammon believed that any protection offered by GG would 
only last a few weeks, so it needed to be administered at the early stages of an epidemic when 
passive immunization could offer the most protection. Since parents could decide whether or when 
to volunteer their children, the faster the maximum cohort was achieved, the greater the 
opportunity to assess GG. The field team needed to react quickly and be prepared to inject 
thousands of children in temporary clinics. By anticipating parental anxieties in publicity materials, 
Foundation officials hoped to provide Hammon with steady enrolment and protocol compliance. 
 When a high-incidence polio epidemic erupted in Utah in 1951, Hammon and Foundation 
officials launched their experiment. They moved supplies to a staging site in Provo and instigated a 
publicity program to build local support. Because of state medical licensing laws, only Utah doctors 
could administer the test sera, making it necessary for Hammon to direct his initial publicity efforts 
to physicians. To Hammon’s astonishment, local doctors made the experiment their own, seeing 
participation as a professional duty and a form of public health activism. They not only agreed to 
administer the injections, but also volunteered their own children to the experiment. In addition, 
radio announcers interviewed members of Hammon’s team, while journalists attended a clinic 
demonstration where researchers submitted to injections to show their faith in the study. 
Like doctors, Utah residents strongly supported Hammon’s study. Long lines snaked around 
the clinics, as parents accompanied their children to the injection tables. Although the success of 
Hammon’s study hinged on accurate clinical records and adherence to the protocol, local 
enthusiasm began to undermine data quality. Some parents illicitly attended more than one clinic to 
increase the likelihood of their children receiving GG over placebo, which undermined the statistical 
merit of the study. Although Hammon could not determine the number of multiple enrollments, the 
practice highlighted a tension between scientific accuracy and the hopes of desperate parents. In an 
effort to prevent multiple enrollments, Utah doctors were asked to wipe a common laboratory 
phenol reagent on the buttock of each child as a temporary indicator of participation. Meanwhile, 
other parents chose to attend clinics outside of their enrolment areas to avoid disappointment if 
supplies were exhausted. Hammon also discovered that local volunteers secretly redistributed the 
test sera to the favor of their own communities. Citizen intervention in the supply chain showed the 
power that some residents exercised over the study and how their actions undermined the creation 
of scientific knowledge. Although Hammon was frustrated by the illicit redistribution of the serum 
and the multiple clinic enrolments, he remained optimistic about the experiment. Over 5,000 
children had been injected and it was evident that parents and doctors would support scientific 
research. As statisticians determined that at least another 50,000 children were needed for a 
significant result, Hammon expanded his experiment. 
Since polio was more prevalent during warmer months, the experiment continued the 
following summer. When a devastating epidemic struck Texas in July 1952, with hundreds of cases of 
paralysis, Hammon decided that Houston and surrounding Harris County would be an ideal test 
site.10 With Foundation support and the assistance of local doctors, politicians, religious leaders, and 
journalists, he actively promoted the GG study. The publicity program was so successful that some 
parents not only enrolled their children at Hammon’s clinics, but then asked their family doctors to 
administer injections of the blood fraction afterwards. Hammon attempted to discourage this 
practice, since it threatened the accuracy of his data set. When such efforts failed, he moved his 
injection clinics out of non-compliant areas. In addition, some Texas pharmaceutical suppliers built 
on Hammon’s publicity campaign by promoting their own GG supplies, leading to sales of over 
20,000 cc. of the blood fraction to local residents. Of the 35,000 children enrolled in the Texas study, 
Hammon could not be certain how many had received private doses of GG. An effective marketing 
campaign combined with parental anxiety at a time of crisis coalesced to shatter the statistical value 
of the GG study. 
Pressure to obtain more data led Hammon and the Foundation to expand the study to Iowa 
and Nebraska, where they achieved better compliance to the protocol. While Hammon enrolled an 
additional 15,000 children at these test sites, it was clear that the experimental data was already 
tainted. Hammon’s lack of power over trial conduct and compliance, combined with the 
Foundation’s focus on promoting the experiment, created a wave of optimism that was difficult to 
contain. Hammon was forced to assess data of dubious quality. When the results of the experiment 
were finally published, Hammon’s decision not to acknowledge these serious shortcomings 
facilitated a claim that GG worked for the prevention of polio paralysis under epidemic conditions.1-5 
Because the experiment had been expensive to undertake, other researchers could not corroborate 
the results. When the Foundation trumpeted the scientific success of the study, Hammon became 
America’s foremost polio warrior. 
Due to prevailing optimism about GG, the Foundation spent millions of dollars to procure 
hundreds of gallons of the blood fraction for a national polio immunization program in 1953 and 
1954. Over 220,000 children received injections across America and 1,728,700 cc. of GG was 
administered. Although many parents and health professionals had no reason to doubt the value of 
the blood fraction to fight polio, evidence began to emerge that it was not effective. When data was 
collected about the national program in 1953, the WHO Expert Committee on Poliomyelitis and the 
United States Public Health Service delivered cutting indictments. 
The embarrassment surrounding the ill-fated use of GG was salvaged by the field testing of 
Dr. Jonas Salk’s killed-virus vaccine. Foundation officials called on their experience with GG when 
designing the Salk polio vaccine trial. They were confident that an enormous civilian experiment was 
possible, since the GG study showed that parents would volunteer their children to an experiment 
that did not guarantee efficacy or safety. They also refined publicity materials, including films, radio 
announcements, and posters. In an effort to increase the perceived scientific rigor and impartiality 
of the test, Foundation officials established the Vaccine Evaluation Center at the University of 
Michigan under the leadership of Dr. Thomas Francis Jr. Following a massive trial, Francis declared 
the Salk vaccine to be safe and effective and it was licensed on April 12, 1955. Unlike GG, it could be 
administered before an epidemic and provide durable immunity to all three types of poliovirus. 
Although the vaccine marked a major milestone in the polio eradication effort, the earlier testing of 
GG offered important lessons for researchers and their sponsoring agencies concerning how 
marketing and parental anxiety could inadvertently affect the generation of accurate scientific 
evidence. 
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